je.st

Home › meets

Tag: meets

More than meets the eye in 'commercial' vs. 'not for profit'

2016-11-09 19:00:00| Oil IT Journal - www.oilit.com

Neil McNaughton reports back from the 2016 Intelligent Energy conference on its role in breaking down the silo walls between IT and 'the business.' While IE and its Digital Energy twin do a good job, they face increasing competition from the 'for-profit' user groups such as the Esri PUG, the OSIsoft user conference and the Spotfire Energy conference. All to be reported from 'real soon now!'

Tags: not commercial vs eye

Hazmat Transport Pros Lack Confidence That Supply Chain Meets Compliance

2016-11-02 16:01:00| Coatings World Breaking News

Tags: supply transport lack chain

Metal parts manufacturer meets needs of many industries

2016-11-01 01:28:12| Canadian Plastics Headlines

Matritech prides itself on being an extension of its customers companies, regardless of the industry they are in. The post Metal parts manufacturer meets needs of many industries appeared first on Canadian Plastics.

Tags: parts metal manufacturer industries

Mercks KEYNOTE-045 Studying KEYTRUDA (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoint and Stops Early

2016-10-21 12:45:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. KEYTRUDA is the First Immunotherapy to Show Improved Overall Survival Compared With Chemotherapy in Urothelial Cancer KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the phase 3 KEYNOTE-045 trial investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer, met the primary endpoint of overall survival (OS). In this trial, KEYTRUDA was superior compared to investigator choice chemotherapy. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: advanced early primary cancer